Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 3, 1997, Pages 747-752

  File, Sandra E ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Anxiety; CGP 49283; NK1 receptors; Social interaction; Substance P; Tolerance; Withdrawal

Indexed keywords

2 BENZYL 1 (3,5 DIMETHYLBENZOYL) 4 (4 QUINOLINYLMETHYLAMINO)PIPERIDINE; DIAZEPAM; SUBSTANCE P ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; NEUROKININ 1 RECEPTOR; PIPERIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SOCIAL INTERACTION; WITHDRAWAL SYNDROME; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN RELATION; ILLUMINATION; MALE; MENTAL STRESS; MOTIVATION; MOTOR ACTIVITY; PSYCHOLOGICAL ASPECT;

ANIMALS; ANTI-ANXIETY AGENTS; DIAZEPAM; DRUG TOLERANCE; HANDLING (PSYCHOLOGY); INTERPERSONAL RELATIONS; LIGHTING; MALE; MOTOR ACTIVITY; PIPERIDINES; QUINOLINES; RATS; RECEPTORS, NEUROKININ-1; STRESS, PSYCHOLOGICAL;

EID: 0030608890     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)90002-2     Document Type: Article

References (31)

1. Adamec R. E., Saying U., Brown A. The effects of corticotrophin releasing factor (CRF) and handling stress on behavior in the elevated plus-maze test of anxiety. J. Psychopharmacol. 5:1991;176-186.
2. Bannon M. J., Deutch A. Y., Tam S. Y., Zamir N., Eskay R. L., Lee J.-M., Maggio J. E., Roth R. H. Mild footshock stress dissociates substance P from substance K and dynorphin from Met/ and Leu/enkephalin. Brain Res. 381:1986;393-396.
3. Biggio G., Concas A., Corda M. G., Giorgi O., Sanna E., Serra M. GABAergic and dopaminergic transmission in the rat cerebral cortex. Effect of stress, anxiolytic and anxiogenic drugs Pharmacol. Ther. 48:1990;121-142.
4. Cutler, M.: Potential anxiolytic activity in gerbils from the substance P (SP) receptor antagonist, CGP 49823. J. Psychopharmacol. A22;1994.
5. de Lima T. C., Ribeiro S. J. Central effects of tachykinin NK receptor agonists and antagonists on the plus-maze behavior in rats. Soc. Neurosci. Abstr. 22:1996;1154.
6. Elliott P. J., Nemeroff C. B., Kilts C. D. Evidence for a tonic facilitatory influence of Substance P on dopamine release in the nucleus accumbens. Brain Res. 386:1986;379-382.
7. File S. E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods. 2:1980;219-238.
8. File S. E. Animal models for predicting clinical efficacy of anxiolytic drugs. Social behaviour Neuropsychobiology. 13:1985;55-62.
9. File S. E. The history of benzodiazepine dependence. A review of animal studies Neurosci. Biobehav. Rev. 14:1990;135-146.
10. File S. E. The biological basis of anxiety. Meltzer H. Y., Nerozzi D. Current practices and future developments in the pharmacotherapy of mental disorders. 1991;159-166 Excerpta Medica, Amsterdam.
11. File, S. E.: The social interaction test of anxiety. Neurosci. Protocols 010-01-01-07; 1993.
12. File S. E. Chronic exposure to noise modifies the anxiogenic response, but not the hypoactivity, detected on withdrawal from chronic ethanol treatment. Psychopharmacology. 116:1994;369-372.
13. 1A receptor ligands in dorsal raphé and ventral hippocampus. Pharmacol. Biochem. Behav. 54:1996;123-128.
14. 1A receptor modulation of anxiety in two ethological animal tests. J. Neurosci. 16:1996;4810-4815.
15. File S. E., Andrews N., Zharkovsky A. Handling habituation and chlordiazepoxide have different effects on GABA and 5-HT function in the frontal cortex and hippocampus. Eur. J. Pharmacol. 190:1990;229-234.
16. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J. F., Blanchard J. C., Laduron P. M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc. Natl. Acad. Sci. USA. 88:1991;1020-1021.
17. 1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction but not in the elevated plus-maze. Brain Res. 732:1996;145-153.
18. Hasenohrl R. U., Jentiens O., De Souza Silva M. A., Tomaz C., Huston J. P. Anxiolytic action of substance P administered systemically or into the basal forebrain. Soc. Neurosci. Abstr. 22:1996;1152.
19. Hauser K., Heid J., Criscione L., Brugger F., Ofner S., Veentra S., Schilling W. P7/8 CGP 49823, a novel, non-peptidic NK-1 receptor antagonist. In vitro pharmacology Neuropeptides. 26(suppl. 1):1994;37.
20. Helke C. J., Krause J. E., Mantyh P. W., Couture R., Bannon M. J. Diversity in mammalian tachykinin peptidergic neurons. Multiple peptides, receptors and regulatory mechanisms FASEB J. 4:1990;1606-1615.
21. Lavigne G. J., Millington W. R., Mueller G. P. The CCK-A and CCK-B receptor antagonists devazapide and L-365,260 enhance morphine antinociception only in nonacclimated rats exposed to a novel environment. Neuropeptides. 21:1992;119-129.
22. Marchand J. E., Shimonaka H., Kream R. M. Biochemical characterization and anatomical distribution of a major form of unamidated precursor of substance P in rat brain. Brain Res. 567:1991;290-305.
23. 1) receptor antagonist. Science. 251:1991;437-439.
24. Otsuka M., Konishi S. Release of substance P-like immunoreactivity from isolated spinal cord of newborn rat. Nature. 264:1976;83-84.
25. Otsuka M., Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-308.
26. 2 receptor antagonists in the mouse light-dark box. Eur. J. Pharmacol. 250:1993;R11-12.
27. Teixeira R. M., Santos A. D., Ribeiro S. J., Calixto J. B., Rae G. A., De Lima T. C. M. Effects of central administration of tachykinin receptor agonists and antagnoists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14.
28. Unger T., Carolus S., Demmers G., Ganten D., Lang R. E., Maser-Gluth C., Steinberg H., Veelken R. Substance P induces a cardiovascular defence reaction in the rat. Pharmacological characterization Circ. Res. 63:1988;812-820.
29. Vassout A., Schaub M., Gentsch C., Ofner S., Schilling W., Veenstra S. CGP 49823, a novel NK-1 receptor antagonist. Behavioural effects Neuropeptides. 26(suppl. 1):1994;38.
30. 2 receptor antagonist, in rodent and primate models of anxiety. Psychopharmacology. 121:1995;186-191.
31. Young A. M., Goudie A. J. Adaptive processes regulating tolerance to behavioural effects of drugs. Bloom F. E., Kupfer D. J. Psychopharmacology. The fourth generation of progress:1995;733-742 Raven Press, New York.